ea0063p587 | Diabetes, Obesity and Metabolism 2 | ECE2019
Leclerc Helene
, Drui Delphine
, Mahot-Moreau Pascale
, Pichelin Matthieu
, Thomare Patrick
, Landau Ester
, Fournier Anne-Laure
, Fronteau Clementine
, Dresco Eric
, Lucas-Pouliquen Bernadette
, Cariou Bertrand
Introduction: Nivolumab is an anti-PD1 immunotherapy that restores the immune response against cancer cells, but can induce fulminant diabetes. The prevalence of such anti-PD1 induced diabetes is not clearly determined, but it has been recently estimated between 0.4% and 0.9% in recent studies. Here, we performed a monocentric epidemiological study in order to assess the prevalence and provide a description of Nivolumab-induced diabetes cases.Material an...